FENC
Fennec Pharmaceuticals Inc. (NASDAQ)
Healthcare — Biotechnology
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Price History
Fundamentals
| Market Cap | $359.18M |
| P/E Ratio (TTM) | - |
| Forward P/E | 11.62 |
| EPS (TTM) | $-0.29 |
| Dividend Yield | - |
| Profit Margin | -16.42% |
| Revenue Growth | 72.60% |
| ROE | -52.68% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $15.67 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 73.6 |
| Beta | 1.08 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $11.31 |
| 52-Week Low | $5.65 |
| 50-Day Avg | $8.67 |
| 200-Day Avg | $8.09 |
| Avg Volume | 275.6K |
| Volume | 102.6K |
Performance Analysis
BULLISHFENC shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:09 UTC
Back to Screener Export Report